Bacterial Eavesdropping for Fast Antibiotic Susceptibility Testing

SoundCell technology aims to revolutionize antimicrobial susceptibility testing by reducing diagnostic time to under 1 hour, improving treatment outcomes and lowering healthcare costs.

Subsidie
€ 2.499.143
2023

Projectdetails

Introduction

Antimicrobial resistance (AMR) is a global health problem, endangering millions of lives. Rapid Antimicrobial Susceptibility Testing (AST) plays a crucial role in determining the type and concentration of antibiotics required to inhibit the growth of a pathogen.

Current Challenges

However, the major issue with the current ASTs is the slow diagnostics, ranging from 24 hours to a few days. This delay leads to mis-prescriptions and/or over-prescriptions, thus severely impacting treatment outcomes.

SoundCell Technology

At SoundCell, we developed SoundCell technology, a breakthrough technique that reduces the AST time from a few days to less than 1 hour. It is a graphene-based biosensor technology that uses nanomechanical vibrations of ultrathin micron-sized graphene drums to detect the motion of a single bacterium.

Motion Detection

We demonstrated that the motion of alive and dead bacteria is different when adhered to the graphene sensors, and we can correlate such changes to antibiotic susceptibility.

Project Goals

During the EICT, we will mature SoundCell technology into a high-throughput, cost-effective AST. Our goals include:

  1. Developing high-volume manufacturing methods.
  2. Engineering a user-friendly low-cost prototype readout system.
  3. Validating our AST prototype in 2 clinical labs through testing of a variety of pathogenic clinical isolates.
  4. Benchmarking the speed and sensitivity of our platform against other AST techniques.
  5. Establishing our exploitation strategy and regulatory roadmap.
  6. Developing and executing the business model.
  7. Engaging stakeholders.

Expected Outcomes

SoundCell technology will directly lower healthcare expenses by shortening hospital stays with fewer lab and diagnostic tests. It will also improve clinical outcomes for patients by reducing recovery time, secondary complications, and mortality.

Intellectual Property

We have filed 2 patent applications and envision another 4 patents over the project duration.

Financial Forecast

By 2030, we forecast revenues of 17 million and employment for up to 60 personnel.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.499.143
Totale projectbegroting€ 2.499.143

Tijdlijn

Startdatum1-11-2023
Einddatum31-10-2026
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • SOUNDCELL B.V.penvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen EIC Transition

EIC Transition

AUTOMATED CLINICAL PLATFORM FOR PERSONALIZED ANTIBIOTHERAPY IN CRITICAL UNITS BASED ON SURFACE ENHANCEMENT RAMAN SPECTROSCOPY

ACU-SERS aims to revolutionize antibiotic dosing in sepsis patients by providing a fast, automated, and cost-effective system for therapeutic drug monitoring, enhancing clinical outcomes and commercial viability.

€ 2.499.997
EIC Transition

Rapid Affordable Microbiota Analysis at the point of Need

BforCure's RAMAN project aims to develop a rapid, affordable microbiota analysis device for point-of-need testing, enhancing health and production outcomes in various sectors.

€ 2.466.223

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

GAAFSTE: GrAfeen nAnosensoren voor Fast (snelle) antibiotica Susceptibiliteit TEst

Dit project ontwikkelt een snel prototype voor antibiotica susceptibiliteitstests, dat binnen 2 uur resultaten levert, om de effectiviteit van antibiotica te optimaliseren en resistentie tegen te gaan.

€ 275.555
ERC Proof of...

Rapid chip-based detection of antibiotic resistances

Developing ResisCHIP, a rapid RNA diagnostic tool for bacterial infections, to enhance treatment selection and combat antimicrobial resistance within 2 hours from blood samples.

€ 150.000
1.1 - Het ve...

A Novel Rapid Antibiotic Susceptibility Testing Device to Enhance Hospital Patient Outcomes - KAIROS

KAIROS ontwikkelt een sneltestapparaat voor antibiotica-gevoeligheid om de behandeling van infecties te versnellen en patiëntresultaten te verbeteren.

€ 1.228.072
ERC Proof of...

self-PoweRed cONductimeter for digiTalization of rapid mOlecular diagnostics

PRONTO aims to develop a low-cost, self-powered conductimetric sensor for rapid, sensitive detection of infectious diseases, making advanced testing accessible in low- and medium-income countries.

€ 150.000
Mkb-innovati...

RADAR

RADAR ontwikkelt een platformtechnologie voor snelle en nauwkeurige diagnose van urineweginfecties en antibioticaresistentie.

€ 168.350